We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

200 hedge funds and large institutions have $5.01B invested in Intercept Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 78 increasing their positions, 53 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 23

107% more capital invested

Capital invested by funds: $2.42B → $5.01B (+$2.58B)

47% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 53

18% more funds holding

Funds holding: 169200 (+31)

14% more call options, than puts

Call options by funds: $257M | Put options by funds: $225M

Holders
200
Holders Change
+31
Holders Change %
+18.34%
% of All Funds
5.33%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
54
Increased
78
Reduced
53
Closed
23
Calls
$257M
Puts
$225M
Net Calls
+$31.7M
Net Calls Change
+$71.9M
Name Holding Trade Value Shares
Change
Change in
Stake
AIM
151
Artemis Investment Management
United Kingdom
$444K +$341K +1,573 New
BF
152
BOK Financial
Oklahoma
$440K +$338K +1,560 New
AB
153
Amalgamated Bank
New York
$422K +$29.7K +137 +10%
CSS
154
Cubist Systematic Strategies
Connecticut
$421K +$280K +1,293 +647%
NMIMC
155
Northwestern Mutual Investment Management Company
Wisconsin
$415K +$318K +1,470 New
Verition Fund Management
156
Verition Fund Management
Connecticut
$407K +$312K +1,442 New
FPCP
157
Fort Point Capital Partners
California
$402K +$309K +1,425 New
DFIM
158
Detwiler Fenton Investment Management
Massachusetts
$396K -$18.8K -87 -6%
Envestnet Asset Management
159
Envestnet Asset Management
Illinois
$393K +$302K +1,393 New
Stifel Financial
160
Stifel Financial
Missouri
$347K -$41.1K -190 -13%
RCM
161
Reynolds Capital Management
Nevada
$338K +$260K +1,200 New
FPC
162
Falcon Point Capital
California
$303K +$233K +1,074 New
Canada Life
163
Canada Life
Manitoba, Canada
$300K
MIM
164
Marco Investment Management
Georgia
$282K -$346K -1,600 -62%
BPC
165
Banque Pictet & Cie
Switzerland
$282K +$217K +1,000 New
BCM
166
BlueCrest Capital Management
Jersey
$282K +$217K +1,000 New
IG
167
ING Group
Netherlands
$282K +$217K +1,000 New
MLICM
168
Metropolitan Life Insurance Company (MetLife)
New York
$265K +$13.4K +62 +7%
M&T Bank
169
M&T Bank
New York
$262K -$530K -2,449 -73%
BNP Paribas Financial Markets
170
BNP Paribas Financial Markets
France
$259K +$196K +903 +5,644%
Prudential Financial
171
Prudential Financial
New Jersey
$251K +$193K +890 New
AAM
172
Advisors Asset Management
Colorado
$247K -$1.73K -8 -0.9%
CA
173
Commerzbank Aktiengesellschaft
Germany
$222K -$14.8M -68,285 -99%
Teacher Retirement System of Texas
174
Teacher Retirement System of Texas
Texas
$216K +$79K +365 +91%
ID
175
Integral Derivatives
New York
$214K +$164K +758 New

ICPT Hedge Fund Activity: Q1 2015 in Review

200 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2015, worth a combined $5.01B — up 107% from $2.42B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new ICPT positions and 23 closed out — a net gain of 31 holders — while 78 added to existing stakes and 53 trimmed.

The largest buyer was Ameriprise, adding an estimated $161M. The largest seller was OrbiMed, cutting an estimated $79M.

  • 200 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2015, up from 169 in Q4 2014.
  • Funds reported $5.01B of Intercept Pharmaceuticals, Inc. stock for Q1 2015, up 107% quarter-over-quarter.
  • 54 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2015 and 23 closed out, a net change of +31 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2015 was Ameriprise, an estimated $161M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q1 2015 was OrbiMed, an estimated $79M sold.

Based on aggregated 13F filings for Q1 2015.